Palisade Bio (PALI) Capital Expenditures Growth (1y) (2011 - 2019)
Palisade Bio (PALI) Capital Expenditures Growth (1y) (2011 - 2019) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,094.26 Bn | 68,093.97 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,939.09 Bn | 1,939.02 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 473.53 Bn | 468.74 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 123.34 Bn | 116.09 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 70.13 Bn | 61.38 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.96 Bn | 62.96 Bn | - | - |
| 8 | Argenx Se | 56.38 Bn | 51.20 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn | 143.40% |
| 10 | Palisade Bio | 422.47 Mn | 289.84 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2019 | -578.13% |
| Dec 31, 2018 | 82.21% |
| Mar 31, 2018 | 2,415.72% |
| Sep 30, 2017 | -88.40% |
| Jun 30, 2017 | -710.32% |
| Mar 31, 2017 | 101.13% |
| Sep 30, 2016 | -13.82% |
| Jun 30, 2016 | 101.99% |
| Mar 31, 2016 | -187.40% |
| Dec 31, 2015 | 34.54% |
| Sep 30, 2015 | 378.93% |
| Jun 30, 2015 | -112.08% |
| Dec 31, 2014 | 131.40% |
| Sep 30, 2014 | -77.23% |
| Jun 30, 2014 | 8,861.53% |
| Dec 31, 2013 | -1,361.56% |
| Sep 30, 2013 | 155.59% |
| Jun 30, 2013 | 89.86% |
| Dec 31, 2012 | 105.23% |
| Sep 30, 2012 | 806.74% |